Logo

Caliper Acquires Cell-Based Screening Technology from Amphora

May 06, 2004

NEW YORK, May 6 (GenomeWeb News) - Caliper Life Sciences, of Hopkinton, Mass., will acquire technology developed for cell-based screening assays by Amphora, of Research Triangle Park, N.C., the companies said today. Caliper will use the technology to develop a new calcium-flux assay for G-protein-coupled receptor drug targets.

 

Amphora will transfer to Caliper its proprietary cell culture techniques, as well as hardware and software upgrades that Amphora has integrated into Caliper's microfluidic screening system. In exchange, Caliper will compensate Amphora with cash, products, and royalties based on future sales of cell-based assays, the companies said.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.